FDA opens pilot to speed preparation for first-in-human drug trials

The U.S. Food and Drug Administration opened applications on September 15 for its finalized Expedited Investigational New Drug pilot, testing a different way to prepare experimental medicines for their first human trials. The initiative could affect the development infrastructure used for future therapies addressing chronic and age-related disease, although it establishes no treatment benefit itself.

Applications are due October 30, 2026. FDA expects an initial cohort of eight to 10 partnerships between drug sponsors and qualified research institutions. The program forms part of the federal Operation TrialBlazer initiative to modernize clinical development.

Its central question is practical: can earlier scientific collaboration and regulatory feedback reduce avoidable delays before clinical testing begins?

Moving review earlier

Most pilot activity will occur before a sponsor files its complete investigational new drug application, or IND. A research institution will help assess the scientific rationale and supporting evidence for individual application components before those components reach FDA.

The agency will then review completed components on a rolling basis. Each submission should be a coherent, self-contained package, rather than a fragmentary collection of data. The sequence can follow the development program’s needs instead of a prescribed order.

This changes when problems can be identified. Manufacturing questions or gaps in nonclinical evidence could be addressed while other work continues, potentially reducing late surprises.

The final, complete IND still starts the 30-day review window. Sponsors remain accountable for the completeness of their applications, including when they authorize a research partner to submit information on their behalf.

A limited cohort with safeguards

FDA will prioritize novel candidates without existing clinical experience, intended for commercial development and a first-in-human Phase 1 trial in the United States. Applicants need enough preliminary nonclinical evidence for the agency to assess whether their proposed development timeline is credible.

Selection will consider the severity of the target condition, unmet medical need, and whether the partnership adds meaningful scientific value. The agency intends to include different therapeutic areas, product types, sponsor sizes and research organizations.

The application process evaluates the sponsor and institution together. Each completes a separate form, which the sponsor submits as a combined package. Their business relationship is established outside FDA; the agency says its role in that relationship is to confirm that an official agreement exists.

Regulatory authority remains with FDA. Participation does not change the standards governing IND review or trial conduct. Institutions must manage conflicts of interest, and a partnership can be removed if conflicts compromise objective recommendations.

What success would—and would not—mean

FDA’s stated goals include better submissions, earlier resolution of scientific questions and fewer clinical holds or requests for additional information. The program also encourages coordination of ethics review and trial-site preparation where appropriate. Those are intended operational improvements, not results already demonstrated by the pilot.

Sponsors and institutions will provide written and verbal feedback through trial initiation. With only a small initial cohort, interpretation of any apparent improvement will require attention to the programs selected and the support they received.

For healthspan research, the potential value is an earlier opportunity to test whether a plausible therapy is safe enough to develop further. Entering a human trial does not establish that a drug prevents disability, treats chronic disease successfully or extends healthy life.

FDA currently lists December 18 for participant selection and notification, while noting that its schedule may vary with application volume. The next concrete milestone is therefore the selection of development programs; evidence that this approach actually improves trial readiness will have to follow.